Anxiety & Depression · Texas behavioral health news
RFK Jr. suggests psychedelic therapy for depression and trauma has Trump administration's support - PBS
Anxiety & Depression (Google News) · July 16, 2025
In plain language
Federal health officials are considering a faster path to approve psychedelic drugs like MDMA and ibogaine for conditions such as depression and PTSD. While these substances are currently illegal, new government leaders aim to review clinical data more quickly, potentially within the next year. Supporters believe these treatments offer hope for veterans and those with hard-to-treat trauma. However, some medical experts worry that moving too fast could bypass important safety checks needed to protect patients and ensure the drugs truly work.
AI-generated summary of the source article. Not medical advice.
Key takeaways
- The federal government may reduce review times for psychedelic therapies to as little as one month.
- Texas recently approved $50 million to study ibogaine for treating opioid addiction and PTSD.
- Health officials are exploring ways to be more flexible with traditional research requirements for these drugs.
- Ibogaine shows promise for trauma but carries risks of dangerous irregular heart rhythms.
- Some researchers worry that rushing the approval process could discredit the science behind psychedelic medicine.
RFK Jr. suggests psychedelic therapy for depression and trauma has Trump administration's support PBS
Need to talk to someone in Texas? Browse Texas-licensed telehealth therapists. In crisis, call or text 988.